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1. Introduction
  Diabetes is a chronic metabolic disorder due to absolute or 
relative lack of insulin and characterized by hyperglycemia 
in the postprandial and or fasting state, associated with 
ketosis and protein wasting in severe condition[1]. Globally, 
it is the most common serious and largest endocrine 
disorder and considered to be one of the five leading 
causes of death in the world[2]. In both type 1 and 2 
diabetics, cardiovascular diseases increases two to three 
fold morbidity and mortality rate compared to non-diabetic 
persons[3]. The free radicals derived from oxygen have 
been implicated in the pathophysiology of various disease 
conditions, including diabetes mellitus. The biomolecules 
such as lipids, carbohydrates, proteins, nucleic acids, 
and macromolecules of connective tissue are affected 
by free radicals. Also, the evidence showed diabetes 
induced changes in the activities of antioxidant enzymes 
in various tissues[4]. Moreover, oxidative stress is involved 
in the development and progression of diabetes associated 
complications. The activation of transcription factors, 
advanced glycated end products (AGEs) are believed to 
be partly responsible for the oxidative stress and diabetic 
complications[5]. 
  Despite the availabilities of hypoglycaemic agents 
from natural and synthetic sources, diabetes and its 
complications continue to be a major healthcare problem. 
Also, there is a clinical unmet need is existing in the 
treatment of diabetes. In Ayurvedic and Siddha medicines, 
there are number of Indian medicinal plants which have 
found to be useful to successfully manage diabetes[6]. The 
advantage of traditional medicinal plants is no or lesser 
adverse effects with multiple therapeutic actions due to the 
presence of different bioactive compounds. World Health 
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Organization (WHO) has recommended the evaluation of 
traditional plants for the diabetes treatment due to its non-
toxic, with less or no side effects and efficacy are considered 
to be useful for diabetes management[7].
  Tectona grandis (T. grandis) Linn. f. (Verbenaceae), 
commonly known as teak, is distributed throughout India 
in deciduous forests and also cultivated. The whole tree of 
T. grandis is medicinally important and many reports on 
claims to cure several diseases in Indian traditional system 
of medicine particularly in Ayurveda and in folklore[8]. 
The flowers of T. grandis are acrid, bitter, refrigerant, 
depurative, diuretic and anti-inflammatory, and useful in 
vitiated conditions of pitta and kapha, burning sensation, 
dipsia, leprosy, skin diseases, strangury and diabetes[8,9]. 
The preliminary phytochemical analysis of METGF revealed 
presence of tannins and phenolic compounds[10]. It is well 
known that diverse phytoconstituents from this group 
were reported for many pharmacological actions including 
antidiabetic activity. Moreover, up-to-date literature 
research revealed that there is no scientific report on 
T. grandis flowers to supports its use in the treatment 
of diabetes. Hence, objective of the present study is to 
investigate antidiabetic, antihyperlipidemic and antioxidant 
potential of methanol extract of T. grandis flowers in STZ-
induced diabetic rats to generate significant scientific data 
to supports its traditional use.
2. Materials and methods
2.1. Plant material and extraction
  T. grandis Linn. f. (Verbenaceae) flowers were collected 
from Annaikatti, Coimbatore, Tamil Nadu, India. The 
specimen was authenticated at Botanical Survey of India 
(BSI), Coimbatore (BSI/SC/5/23/09-10/Tech.-486). The 
flowers (60 g) were shade dried, powdered and extracted 
with petroleum ether (60-80 曟) and methanol using 
soxhlet apparatus. The extracts was concentrated in rotary 
evaporator at 35-40 曟 under reduced pressure. The METGF 
was stored at 2-8 曟 until the completion of pharmacological 
studies and yield of the extract was 21.62% (w/w). 
2.2. Experimental animals
  Male Wistar albino rats (150-180 g) were used to assess 
the oral glucose tolerance test and anti-diabetic activity. 
In acute toxicity study, female Wistar rats (150-170 g) were 
used and all animals were kept and maintained under 
standard laboratory conditions. The animals were fed 
with standard laboratory diet and allowed to drink water 
ad libitum. Studies were carried out in accordance with 
institutional ethical guidelines for the care of laboratory 
animals of KMCH College of Pharmacy, Coimbatore, India 
(approval no. KMCRET/Ph.D/5/09).
2.3. Chemicals
  Streptozotocin and all other chemicals used in this study 
were analytical grade and were procured from Himedia 
Laboratories, Mumbai, India. For the estimation of 
biochemical parameters, kits were procured from Primal 
Healthcare Limited, Lab Diagnostic Division, Mumbai, 
India.
2.4. Acute toxicity study
  Acute oral toxicity study was performed as per Organization 
for Economic Cooperation and Development guidelines 
423[11]. After the oral administration of METGF, animals 
were observed individually at least once during the first 30 
min, periodically during the first 24 h, with special attention 
given during the first 4 h, and daily thereafter, for a total of 
14 d observed for toxicity determination.
2.5. Oral glucose tolerance test
  Oral glucose tolerance test (OGTT) was performed in 
overnight fasted normal rats as per reported method[12]. 
The blood glucose levels were determined by using glucose 
meter (Glucocard™ 01-mini, Arkray Factory, Inc., Japan) by 
glucose oxidase-peroxidase method using strips.
2.6. Induction of experimental diabetes
  Diabetes was induced in overnight fasted rats by 
STZ (60 mg/kg, ip.) after dissolving in freshly prepared 
cold citrate buffer (0.1 mol/L, pH 4.5)[13]. STZ induce fatal 
hypoglycemia as a result of massive pancreatic insulin 
release, the rats were provided with 5% dextrose solution 
after 6 h of STZ administration for next 24 h to prevent 
hypoglycemia[14]. Diabetes was confirmed 72 h after 
induction by measurement of tail vein blood glucose levels 
with the glucose meter. Diabetic rats were kept 14 d under 
standard laboratory condition for the stabilization of blood 
glucose level[15]. After 14 d induction of diabetes, blood 
glucose was again determined and only animals with a blood 
glucose level greater than 300 mg/dL were selected for the 
study.
2.7. Experimental design for antidiabetic activity
  The rats were divided into five groups each consists 
of a minimum of six animals. The group 1: control rats 
received propylene glycol (5 mL/kg); group 2: STZ-induced 
diabetic rats received propylene glycol (5 mL/kg); group 3: 
diabetic rats received METGF 100 mg/kg; group 4: diabetic 
rats received METGF 200 mg/kg and group 5: diabetic 
rats received glibenclamide 5 mg/kg[16]. The vehicle, 
METGF and glibenclamide were administered orally to the 
respective group animals for 28 d. The fasting body weight, 
blood glucose level were estimated on 0, 7, 14, 21 and 28 d 
periodically. Urine glucose and ketone levels determined 
using commercially available strips. At the end of 
experimental period, overnight fasted animals were received 
respective treatment and after 1 h treatments all animals 
were anaesthetized with ketamine (100 mg/kg, i.p.); blood 
sample was collected through retro-orbital plexus puncture 
and stored in with or without disodium ethylene diamine 
tetra-acetate for the biochemical parameters estimation. 
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2.8. Measurement of biochemical parameters
  Blood glucose, Hb, HbA1c was estimated using whole 
blood. The high density lipoprotein (HDL), total cholesterol 
(TC), triglycerides (TG), serum glutamate-pyruvate 
transferase (SGPT) and glutamate-oxaloacetate transaminase 
(SGOT), total protein, creatinine, uric acid and urea were 
estimated in serum by kits specific for the test using semi-
autoanalyzer (Photometer 5010V5+, Germany). The serum 
insulin was determined by radioimmunoassay method[17]. 
The LDL and VLDL levels was calculated by the following 
equation[18]:
 VLDL = Triglycerides/5
 LDL = TC - HDL - VLDL
2.9. Determination of antioxidant levels
  Liver and kidney samples were dissected out and washed 
immediately with ice cold saline to remove blood. The 
lipid peroxidation determined by determined measuring 
thiobarbituric acid reactive substances (TBARS). The 
antioxidant such as superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPx) and reduced glutathione 
(GSH) were estimated in liver and kidney[19]. 
2.10. Histopathological investigation
  The animals were sacrificed and pancreas was dissected 
out, washed in normal saline, for histopathological studies. 
Pancreatic tissues were fixed in10% formalin, dehydrated 
with 50%-100% ethanol solution, and embedded in paraffin. 
The sections of 5 毺m thick were cut and stained with 
hematoxylin-eosin then examined under light microscope.
2.11. Statistical analysis
  All the data expressed as mean依SEM were evaluated by 
one-way analysis of variance (ANOVA), followed by Dunnett曚s 
test for multiple comparisons using Prism GraphPad version 
5.0 and values of P<0.05 were considered as statistically 
significant.
3. Results
3.1. Acute toxicity study
  The oral administration of METGF in rats up to the dose 2 
000 mg/kg did not exhibit any signs of toxicity for 14 d and no 
animals were died. It indicates that METGF was nontoxic in rats 
up to an oral dose of 2 000 mg/kg of body weight. Therefore, the 
biological evaluation was carried out using 1/5 and 1/10 dose of 
METGF ie. 100 and 200 mg/kg dose levels.
3.2. Effect of METGF on OGTT
  Glucose challenge to normal rats increased blood glucose 
levels with maximum level at 60 min and returned to normal 
level at 240 min. The METGF administration improved glucose 
tolerance significantly (P < 0.001 and P < 0.01) at 30 min to 120 
min compared to diabetic control animals (Figure 1). 
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Figure 1. Effect of METGF on oral glucose tolerance test (n=6). 
aP < 0.001 METGF 100 and 200 mg/kg compared with diabetic 
control group; bP < 0.01 METGF 100 mg/kg compared with diabetic 
control group.
 
3.3. Effect of METGF on blood glucose and body weight
  The administration of STZ increased blood glucose levels 
significantly compared to the control rats. The oral treatment 
of METGF (100 and 200 mg/kg) and glibenclamide (5 mg/kg) 
showed significant (P<0.001) reduction in blood glucose level 
of the diabetic rats. At a dose 200 mg/kg of METGF produced 
greater hypoglycemic effect (P<0.01) than METGF 100 mg/
kg (Table 1). There was a significant (P<0.05, P< 0.01 and 
P<0.001) reduction in body weight after the administration of 
STZ compared to control group animals (Figure 2). However, 
this significant weight loss is prevented after the treatment 
of both doses of METGF and glibenclamide in diabetic rats.
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Figure 2. Effect of METGF on body weight in STZ-induced diabetic 
rats (n=6).
aP < 0.05 and bP < 0.01 diabetic control compared with control group; 
cP < 0.001 diabetic control compared with control group; dP < 0.01 
glibenclamide 5 mg/kg compared with diabetic control group; eP < 
0.001 METGF 100, 200 mg/kg and glibenclamide 5 mg/kg compared 
with diabetic control group; fP < 0.05 METGF 200 mg/kg compared 
with diabetic control group; ns: No significance. 
3.4. Effect of METGF on serum insulin, HbA1c, Hb, urine 
sugar and ketone levels 
  The elevated levels of HbA1c, decreased level of Hb and 
serum insulin were observed in STZ-induced diabetic rats 
were significantly (P<0.001) reverted towards normal levels 
after the treatment of METGF and glibenclamide. The METGF 
at a dose 200 mg/kg showed higher (P<0.001) efficacy than 
100 mg/kg dose in diabetic rats. The urine sugar and ketone 
was drastically controlled in diabetic rats treated with 
METGF and glibenclamide compared to diabetic control rats 
(Table 2).
3.5. Effect of METGF on creatinine, total protein, SGOT, 
SGPT, urea and uric acid levels 
  The effects of METGF on the levels of serum creatinine, 
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total protein, SGOT, SGPT, uric acid and urea in control and 
experimental diabetic rats are given in Table 3. In STZ-
induced diabetic rats, the above biochemical parameters 
are significantly (P<0.001) altered compared to control rats. 
The increased levels of creatinine, SGOT, SGPT, uric acid 
and urea were significantly (P<0.001) reduced after the 
administration of both doses of METGF and glibenclamide 
in diabetic rats. The METGF 200 mg/kg treatment showed 
higher reduction of SGOT, urea and uric acid significantly 
(P<0.05 and P<0.001) compared to 100 mg/kg dose. The 
total protein levels in STZ-induced diabetic rats showed 
significant (P<0.001) reduction than control rats and 
administration of METGF and glibenclamide increases total 
protein levels significantly (P<0.01 and P<0.001). 
3.6. Effect of METGF on lipid profiles
  In diabetic rats, significant (P<0.001) elevated level 
of cholesterol, triglycerides, LDL, and VLDL as well as 
decreased level of HDL was observed compared to control 
animals. The administration of both the doses of METGF 
significantly (P<0.001) reduced elevated TC, TG, LDL and 
VLDL levels in diabetic rats. At a dose METGF 200 mg/kg 
showed significant (P<0.01 and P<0.001) higher reduction 
of TC, TG, LDL and VLDL levels in diabetic rats than METGF 
100 mg/kg. Also, diabetic rats treated with METGF 200 mg/kg 
showed significant (P<0.001 and P<0.05) greater reduction 
in TC, VLDL and TG levels compared to glibenclamide. 
Moreover, HDL level was significantly (P<0.001) increased 
in diabetic rats treated with METGF and glibenclamide than 
diabetic control rats. The administration of METGF 200 mg/kg 
increases HDL levels significantly (P<0.001) than METGF 
100 mg/kg (Table 4).
3.7. Effect of METGF on liver and kidney antioxidant levels 
  There was a significant (P<0.001) elevation in TBARS 
levels and reduction in SOD, CAT, GPx and reduced GSH 
levels in liver and kidney of diabetic rats compared to 
control rats. The administration of METGF 100 and 200 mg/kg 
and glibenclamide  significantly (P<0.001) reversed these 
changes to near normal level (Table 5). A significant (P<0.01 
and P<0.05) greater efficacy was observed in METGF treated 
diabetic rats on liver GPx than glibenclamide. 
3.8. Histopathological investigation
  In control animals, histopathological examination showed 
normal structure of 毬-cells in the islet of Langerhans 
on the endocrine portion and normal structure of acini in 
the exocrine portion (Figure 3A). In diabetic control rats, 
nuclear changes, karyolysis and residue of destroyed cells 
were visible. Relative reduction of size and number of islets 
and drastic reduction of 毬-cells were clearly seen (Figure 
3B). Administration of METGF 100 mg/kg to the diabetic rats 
showed minimal necrosis of 毬-cells and lesser damage of 
acini when compared to diabetic control rats (Figure 3C). At 
a dose 200 mg/kg of METGF treated diabetic rats prevented 
毬-cells necrosis, increases number of 毬-cells and size of 
the islets of Langerhans (elongated). Also, METGF treatment 
prevented destruction of exocrine part or reversed the 
damaged acini towards normal when compared to diabetic 
control and METGF 100 mg/kg treated diabetic rats (Figure 
3D). The reference drug, glibenclamide, also prevented the 
destruction of 毬-cells and increases its number as well as 
size than diabetic control rats (Figure 3E).
 
Figure 3. Histopathology of pancreas
3A: Control; 3B: Diabetic control (Black arrow indicates necrosis of 
毬-cells, karyolysis, nuclear changes); 3C: Diabetic rat treated with 
METGF (100 mg/kg); 3D: Diabetic rat treated with METGF (200 mg/
kg); 3E: Diabetic rat treated with glibenclamide (5 mg/kg). All photos 
were taken at 40暳magnification (H & E).
4. Discussion
  In diabetic patients, objective of the treatment is 
to lower blood glucose to near-normal levels[20]. 
I n  p r e s e n t  i n v e s t i g a t i o n ,  t h e  o r a l  g l u c o s e 
to le rance  tes t  revea led  tha t  METGF has  po ten t
 ial to lower the elevated blood glucose levels. The STZ-
induced diabetic rat is one of the animal models that mimic 
the human diabetes mellitus. The necrosis of pancreatic 
毬-cells by STZ causing degranulation and reduction of 
insulin secretion leads to diabetes[21]. The alkylation nature 
of STZ causes 毬-cells DNA strands breaks that induce 
the activation of poly ADP-ribose polymerase followed by 
depletion of lethal nicotinamide adenine dinucleotide (NAD). 
Also, generation of potential free radicals such as nitric 
oxide (NO) by intracellular metabolism of STZ aggravates 
the situation and precipitates the further 毬-cells DNA 
strands breaks[22]. The decrease in body weight, increase in 
food and water intake was commonly observed in diabetes 
and it may be due to metabolic changes caused by lack 
or deficiency of insulin due to destruction of 毬-cells[23]. 
In diabetic rats, drastic reduction in body weight changes 
observed might be the result of degradation or catabolism 
of structural proteins due to unavailability of carbohydrate 
for the energy metabolism[24]. A significant increase in 
body weight of diabetic rats treated with METGF showed the 
blood glucose stabilization effect which in turn prevents the 
loss of body weight. Administration of METGF lowers blood 
glucose in STZ-induced diabetic rats significantly and its 
effect was almost equal to that of glibenclamide. Further, 
this antidiabetic activity was associated with an increase 
in the serum insulin level indicates that METGF may 
stimulates insulin secretion from the remaining 毬-cells or 
regenerated 毬-cells. The histopathological investigation 
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Table 1
Effect of METGF on blood glucose in STZ-induced diabetic rats (n=6).
Treatment Dose (mg/kg)
Blood glucose (mg/dL)
Day 1 Day 7 Day 14 Day 21 Day 28
Control Vehicle 59.50 依 1.83  64.33 依 1.92  70.66 依 0.88  68.00 依 1.52  65.83 依 1.42
Diabetic control Vehicle 557.67 依 12.18   451.17 依 10.39*   440.01 依 11.02*   445.50 依 12.23* 430.67 依 9.96*
METGF 100 482.17 依 13.73 352.17 依 7.40† 264.67 依 9.33† 176.83 依 8.40†   145.50 依 11.69†
METGF 200 527.33 依 17.65    305.33 依 9.49†,‡      212.17 依 11.68†,‡ 148.33 依 6.85†   119.17 依 10.20†
Glibenclamide     5 514.50 依 18.25   285.50 依 13.48† 172.67 依 8.86†    125.17 依 9.88†,‡     96.50 依 4.61†,‡
*P<0.001 Diabetic control compared with control group; †P<0.001 METGF 100, 200 mg/kg and glibenclamide 5 mg/kg compared with diabetic 
control group; ‡P<0.01 METGF 200 mg/kg or glibenclamide 5 mg/kg compared with METGF 100 mg/kg group.
Table 2
Effect of METGF on HbA1c, haemoglobin, serum insulin, urine sugar and ketone in STZ-induced diabetic rats (n=6).
Treatment Dose (mg/kg) HbA1c (%) Hb (g/dL) Serum insulin (毺IU/mL) Urine sugar Urine ketone
Control Vehicle  6.73 依 0.20 13.93 依 0.22 8.54 依 0.12 Nil Nil
Diabetic control Vehicle 14.16 依 0.36*    6.63 依 0.18*  3.55 依 0.15* ++++ Trace
METGF 100 10.76 依 0.27†    8.76 依 0.16†  6.37 依 0.14† Nil Nil
METGF 200      6.81 依 0.18†,‡     14.88 依 0.25†,‡     8.26 依 0.12†,‡ Nil Nil
Glibenclamide     5  6.72 依 0.11†  11.45 依 0.36†  8.40 依 0.21† Nil Nil
*P<0.001 diabetic control compared with control group; †P<0.001 METGF 100, 200 mg/kg and glibenclamide 5 mg/kg compared with diabetic 
control group; ‡P<0.001 METGF 200 mg/kg compared with METGF 100 mg/kg group. ++++ - indicates 110 mmol/L of glucose; Trace - 
indicates 0.5 mmol/L of ketone in urine. 
Table 3
Effect of METGF on serum creatinine, SGOT, SGPT, urea, uric acid, total protein in STZ-induced diabetic rats (n=6).
Treatment Dose(mg/kg) Creatinine(mg/dL) SGOT(U/L) SGPT(U/L) Urea(mg/dL) Uric acid(mg/dL) Total protein(g/dL)
Control Vehicle  0.43 依 0.05   42.50 依 1.05 26.67 依 0.76  14.67 依 0.55 1.55 依 0.06 7.85 依 0.25
Diabetic control Vehicle   0.85 依 0.04* 115.20 依 0.79*  50.83 依 1.07*  94.25 依 1.51*   4.05 依 0.13*  5.38 依 0.12*
METGF 100   0.47 依 0.03†   75.33 依 1.28†  41.00 依 0.85†  75.83 依 2.23†  2.88 依 0.11†   6.18 依 0.11††
METGF 200   0.42 依 0.04†   69.83 依 0.94†,‡  38.67 依 0.88†  34.18 依 1.08†,§      1.92 依 0.04†,§      7.08 依 0.10†,§
Glibenclamide     5   0.37 依 0.02†  46.83 依 1.81†,§  27.33 依 1.05†  29.10 依 0.97†      1.43 依 0.03†,§  7.67 依 0.09†
*P<0.001 diabetic control compared with control group; †P < 0.001 METGF 100, 200 mg/kg and glibenclamide 5 mg/kg compared with diabetic 
control group; ‡P < 0.05 METGF 200 mg/kg compared with METGF 100 mg/kg group; §P < 0.001 METGF 200 mg/kg and glibenclamide 5 mg/kg 
compared with METGF 100 mg/kg group; ††P < 0.01 METGF 100 mg/kg compared with diabetic control group. 
Table 4
Effect of METGF on lipid profile in STZ-induced diabetic rats (n=6).
Treatment Dose (mg/kg)
Serum lipid profile (mg/dL)
Total cholesterol Triglycerides HDL LDL VLDL
Control Vehicle    119.05 依 0.98    131.27 依 1.05 60.15 依 0.74      32.64 依 1.20   26.25 依 0.21
Diabetic control Vehicle    145.72 依 1.15*    161.67 依 1.09*  44.46 依 1.18*      63.93 依 1.87*   32.33 依 0.22*
METGF 100    112.07 依1.39†    140.70 依 1.14†  51.08 依 1.01†      32.85 依 1.19†   28.14 依 0.17†
METGF 200   104.77 依1.31†,‡,§  126.92 依 0.98†,‡,††     57.53 依 0.79†,¶      21.86 依 0.83†,‡  25.38 依 0.20†,§,¶
Glibenclamide     5    116.55 依 1.71†    135.45 依 0.70†     56.13 依 0.93†,‡     33.32 依 1.01†,§   27.09 依 0.14†
*P<0.001 diabetic control compared with control group; †P<0.001 METGF 100 and 200 mg/kg, glibenclamide 5 mg/kg compared with diabetic 
control group; ‡P<0.01 METGF 200 mg/kg or glibenclamide 5 mg/kg compared with METGF 100 mg/kg group; §P<0.001 METGF 200 mg/kg 
compared with glibenclamide 5 mg/kg group; ††P<0.05 METGF 200 mg/kg compared with glibenclamide 5 mg/kg group; ¶P<0.001 METGF 
200 mg/kg compared with METGF 100 mg/kg group.
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Table 5
Effect of METGF on liver and kidney antioxidant enzymes in STZ-induced diabetic rats (n=6).
Treatment Dose
 (mg/kg)
Organ SOD
(U/mg protein)
GPx 
(mg of GSH utilized/
min/mg protein)
Catalase 
(毺mol/L of H2O2/
min/mg protein)
GSH 
(mg of GSH/mg 
protein)
TBARS
(毺M of MDA/ 
min/mg protein)
Control Vehicle Liver 97.17 依 1.22 0.045 7 依 0.001 3   18.94 依 0.89 0.565 依 0.014 112.71 依 3.27
Kidney 98.58 依 1.85 0.043 7 依 0.001 0   15.56 依 0.60 0.568 依 0.012 140.57 依 5.21
Diabetic control Vehicle Liver 75.64 依 1.58* 0.029 6 依 0.001 0*   10.63 依 0.51* 0.379 依 0.016* 272.33 依 6.48*
Kidney 72.51 依 1.36* 0.035 8 依 0.001 1*   10.85 依 0.32* 0.466 依 0.014* 311.27 依 6.03*
METGF 100 Liver 92.53 依 1.59† 0.045 3 依 0.001 5†,‡   15.83 依 0.58† 0.573 依 0.021† 203.17 依 5.46†
Kidney 90.42 依 0.82† 0.041 3 依 0.001 3¶¶   13.26 依 0.26§§ 0.582 依 0.013† 264.32 依 6.67†
METGF 200 Liver 99.26 依 1.21†,¶ 0.046 8 依 0.001 7†,§   17.05 依 0.45† 0.633 依 0.018† 168.06 依 4.49†
Kidney 97.66 依 1.64†,‡‡ 0.042 6 依 0.001 5§§   14.02 依 0.43†† 0.535 依 0.016§§ 211.30 依 6.99†
Glibenclamide    5 Liver 94.68 依 1.29† 0.038 9 依 0.001 2†   16.26 依 0.61† 0.584 依 0.020† 149.09 依 3.86†
Kidney 92.64 依 1.93†  0.0423 依 0.001 2§§   12.66 依 0.40¶¶ 0.561 依 0.015† 191.32 依 5.60†
*P<0.001 diabetic control compared to control group; †P<0.001 METGF 100 and 200 mg/kg, glibenclamide 5 mg/kg compared to diabetic 
control group; ††P<0.001 METGF 200 mg/kg compared to diabetic control group; ‡P<0.05 METGF 100 mg/kg compared to glibenclamide 
5 mg/kg group; ‡‡P<0.05 METGF 200 mg/kg compared to METGF 100 mg/kg group; §P<0.01 METGF 200 mg/kg compared to glibenclamide 
5 mg/kg group; §§P<0.01 METGF 100, 200 mg/kg and glibenclamide 5 mg/kg compared to diabetic control group; ¶P<0.05 METGF 200 mg/kg 
compared to METGF 100 mg/kg group; ¶¶P<0.05 METGF 100 mg/kg and glibenclamide 5 mg/kg compared to diabetic control group. 
clearly supported that METGF has an ability to prevent 
pancreatic 毬-cells damage, increases islets of Langerhans 
size and 毬-cells number and it may leads to increase in 
insulin secretion. Also, increase in insulin level may prevent 
catabolism of structural protein and increase the peripheral 
utilization glucose leading to improvement in body weight 
and reduction in blood glucose levels in the METGF treated 
diabetic rats.
  In diabetic rats, observed increase in the levels of HbA1c is 
due to the persistent hyperglycemia and results in glycation 
of haemoglobin. The concentration of HbA1c correlated with 
diabetic retinopathy, nephropathy and neuropathy and it 
is considered as a tool for the diagnosis and prognosis of 
diabetes associated complications[25]. The increased level 
of HbA1c up to 16% was reported in diabetic patients[26]. In 
diabetes, relative deficiency of insulin leads to decrease 
in protein synthesis in all tissues and thus the synthesis of 
haemoglobin is also reduced[27]. In our study, administration 
of METGF significantly decreased the HbA1c and increased 
Hb levels in diabetic rats. The ability of METGF to decrease 
HbA1c levels in diabetic rats showed its potentiality to 
prevent the diabetic associated complication.
  Liver necrosis in STZ-induced diabetic rats increases 
the activities of SGPT and SGOT in plasma by leakage of 
these enzymes from liver cytosol into the blood stream. 
The metabolic waste such as urea, uric acid, creatinine 
and ions removed by kidney and thus body fluid chemicals 
homeostasis is maintained. But, uncontrolled diabetes also 
associated with renal diseases or damage leads to increase in 
the above metabolites levels in blood. The creatinine levels 
are considered as significant markers of renal dysfunction 
and clinical end point to detect treatment related toxic effect 
of compounds on the kidney in experimental animals[28,29]. 
In the present study, the significant increase in serum SGOT, 
SGPT and creatinine levels were observed in STZ-induced 
diabetic rats represents liver and renal damage compared 
to control rats. Oral administration of METGF reduced 
the elevated levels of SGOT, SGPT and creatinine which 
supports its protective nature on liver tissue and in diabetes 
associated early renal changes.
  Diabetes causes a profound alteration in skeletal muscle 
protein catabolism rather than a decrease in protein 
synthesis due to the insulin deficiency[30]. The imbalance 
between synthesis and catabolism of protein leads to drastic 
alteration in the metabolism of many tissues such as gut, 
skeletal muscle and heart. The protein loss was observed in 
diabetic rats is due to the absence or deficiency of insulin 
in the chemically induced diabetes[31]. The significant 
increase in serum protein levels were observed after the 
treatment of METGF in diabetic rats may also accounts for its 
antidiabetic activity. The end product of protein catabolism 
is urea and enhanced breakdown of liver and plasma protein 
in experimental diabetes leads to the accumulation of 
urea nitrogen[32]. The METGF treated diabetic rats showed 
significant reduction in the elevated levels of serum 
urea indicating the preventive role of METGF in protein 
catabolism. The diabetic vascular complication is mediated 
by oxidative stress. Uric acid has endogenous antioxidants 
action in the body. Therefore, the elevated levels of serum 
uric acid in diabetes may be a protective mechanism of 
body to scavenge free radicals. In oxidative stress, uric 
acid preserves the ability of vascular dilatation of the 
endothelium and prevents alteration of endothelial enzymes 
levels[25]. In our investigation, METGF treatment in diabetic 
rats showed significant reduction in uric acid representing 
indirectly its antioxidant activity.
  Lower-extremity arterial disease, coronary heart disease 
and cerebrovascular disease are frequent vascular 
complications in diabetes. The atherogenic process 
occurrences in vascular diseases are proceeding at a more 
rapid rate in diabetic than in nondiabetic subjects[33]. 
The vascular disease accounts for more than 60% of the 
morbidity and mortality of diabetes that includes both micro 
and macrovascular diseases, and is common in both type of 
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diabetic patients[34]. The elevated cholesterol, triglycerides 
levels and decreased HDL levels as well as LDL particles of 
altered composition were reported in diabetic patients[35]. In 
this study, administration of METGF significantly reduced 
elevated total cholesterol, triglycerides, VLDL and LDL 
levels in diabetic rats. Also, increased level of HDL was 
observed in diabetic rats treated with both the doses of 
METGF and glibenclamide compared to diabetic control rats. 
This action of METGF supports its lipid lowering activity in 
diabetic condition and therefore it helps to prevent diabetic 
associated complication.
  Diabetes is usually accompanied by increased production 
of free radicals or impaired antioxidant defenses. The 
increased oxidative stress has key role in the development 
and progression of diabetes associated complications. The 
various mechanisms involved in the formation of reactive 
oxygen-free radicals and glucose oxidation is believed to 
be the primary source of free radicals. The generation of 
superoxide anion radicals by glucose oxidization and its 
dismutation to hydrogen peroxide, which if not scavenged 
by CAT or GPx, leads to the formation of reactive hydroxyl 
radicals[36,37]. Also, superoxide anion radicals react with 
nitric oxide to form reactive peroxynitrite radicals[38,39]. 
Hyperglycemia promotes lipid peroxidation of low density 
lipoprotein (LDL) by a superoxide-dependent pathway[40-
50]. Moreover, formation of advanced glycation endproducts 
(AGEs) activate the transcription factor nuclear factor 
kappa B (NF-毷B) promoting up-regulation of various NF-
毷B controlled target genes and it enhances production of 
nitric oxide, which is believed to be mediator of islet beta 
cell damage[51,52]. In present study, elevated TBARS levels 
and decreased SOD, CAT, GPx and reduced GSH levels were 
observed in STZ-induced diabetic rats compared to control 
rats. These changes may be due to the glucose oxidation, 
formation of AGEs mediated free radical generation and 
NO donor property of STZ[22]. Administration of METGF 
significantly reduced TBARS and increased SOD, CAT, 
GPx and reduced GSH levels in diabetic rats. The action 
of the METGF to restore the altered antioxidant enzymes 
in STZ-induced diabetic rats indicates its free radical 
scavenging potential and hence it has the ability to prevent 
diabetic associated complication. The present study clearly 
concluded that methanol extract of T. grandis flower 
possess ability to control blood glucose in diabetes. It’s 
antihyperlipidemic and free radical scavenging property 
has potential to prevent diabetic associated complications. 
Our current investigation supports the traditional use of T. 
grandis flower in the treatment of diabetes.
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